eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2023
vol. 40
 
Share:
Share:
abstract:
Original paper

Efficacy of apremilast for psoriasis: a meta-analysis of randomized controlled studies

Yashu Liu
1
,
Yuting Li
1
,
Hanghang Du
2

  1. Department of Dermatology, Banan Hospital of Chongqing Medical University, Chongqing, China
  2. Xi’an Huamei Aesthetic and Plastic Hospital, Shanxi, China
Adv Dermatol Allergol 2023; XL (1): 165-170
Online publish date: 2022/09/06
View full text Get citation
 
Introduction:
The efficacy of apremilast for psoriasis remains controversial.

Aim:
We have conducted a systematic review and meta-analysis to explore the influence of apremilast on treatment efficacy for psoriasis.

Material and methods:
We have searched PubMed, Embase, Web of science, EBSCO, and Cochrane library databases for randomized controlled trials (RCTs) published until February 2022 and assessing the efficacy and safety of apremilast for psoriasis. This meta-analysis was performed using the random-effects model.

Results:
Seven RCTs were included in the meta-analysis. Overall, compared with placebo for psoriasis, apremilast was associated with improved PASI-75 (LOCF) (OR = 6.59; 95% CI: 4.55 to 9.53; p < 0.00001), PASI-75 (NRI) (OR = 6.99; 95% CI: 4.43 to 11.04; p < 0.00001), sPGA response (LOCF) (OR = 5.58; 95% CI: 3.82 to 8.16; p < 0.00001), sPGA response (NRI) (OR = 6.06; 95% CI: 4.07 to 9.02; p < 0.00001), PASI-50 (LOCF) (OR = 4.37; 95% CI: 2.72 to 7.01; p < 0.00001), PASI-90 (LOCF) (OR = 7.81; 95% CI: 2.89 to 21.08; p < 0.0001), adverse events (OR = 1.58; 95% CI: 1.19 to 2.10; p = 0.002), but demonstrated no increase in serious adverse events (OR = 1.01; 95% CI: 0.43 to 2.33; p = 0.99).

Conclusions:
Apremilast is effective and safe to treat psoriasis.

keywords:

apremilast, psoriasis, efficacy, safety, randomized controlled trials

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.